Onconova Therapeutic (ONTX) 3.60 $ONTX Onconova Closes

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Onconova Therapeutic (ONTX) 3.60 $ONTX

Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million
GlobeNewswire - 2 hrs 11 mins ago
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its oversubscribed rights offering ("Rights Offering" for aggregate gross proceeds to the Company of approximately $17.4 million, which is the maximum amount allowable under the terms of this Rights Offering.
ONTX: 3.60 (+0.05)

Onconova Announces Expiration of Oversubscribed Rights Offering
GlobeNewswire - Wed Jul 27, 8:20AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the subscription period for its previously announced rights Offering (the "Offering" of units at a subscription price of $4.10 per unit expired on July 26, 2016, and these rights are no longer exercisable.
ONTX: 3.60 (+0.05)

Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering
GlobeNewswire - Fri Jul 08, 8:20AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced today it has commenced the subscription period for its previously announced rights offering of up to 4,256,186 units consisting of shares of common stock and warrants to purchase shares of common stock to existing stockholders. The rights offering will remain open until 5:00 PM Eastern Time on Tuesday, July 26, 2016, unless extended. Rights holders will need to exercise their subscription rights prior to that date and time.
ONTX: 3.60 (+0.05)

Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data by Onconova collaborators from the U.S. and Europe from the ongoing Phase 2 clinical trial of oral rigosertib in combination with azacitidine in patients with either first- or second-line higher-risk myelodysplastic syndromes (HR-MDS) at the 21 Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, which took place June 9 - 11, 2016.
ONTX: 3.60 (+0.05)

Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 4:00PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.
ONTX: 3.60 (+0.05)

Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
GlobeNewswire - Wed Jun 01, 5:30PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its existing stockholders.
ONTX: 3.60 (+0.05)

Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting
GlobeNewswire - Tue May 31, 7:45AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology Annual Meeting taking place June 3-7 in Chicago, Illinois.
ONTX: 3.60 (+0.05)

Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 3.60 (+0.05), IDXG: 0.30 (unch), PDII: 0.53 (-0.02)

Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split
GlobeNewswire - Fri May 20, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders. At the annual meeting, Onconova stockholders voted to approve a reverse stock split of the company's common stock by a ratio of not less than one-for-eight and not more than one-for-twelve. The company's board of directors subsequently fixed the reverse stock split ratio at one-for-ten and fixed the record date for the reverse stock split.
ONTX: 3.60 (+0.05)

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
ONTX: 3.60 (+0.05)

Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell
GlobeNewswire - Thu Apr 21, 6:00PM CDT
-- More than 30% of all human cancers driven by RAS, a target previously considered "undruggable"--
ONTX: 3.60 (+0.05)

Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans, LA.
ONTX: 3.60 (+0.05)

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the fourth quarter and year-ended December 31, 2015.
ONTX: 3.60 (+0.05)

Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 194.94 (+0.82), ONTX: 3.60 (+0.05), BXLT: 46.02 (-0.18), CELG: 114.16 (+1.97)

Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes
GlobeNewswire - Mon Mar 21, 6:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment of the first European patient in Salzburg, Austria for the Phase 3 INSPIRE trial for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) following failure of hypomethylating agent (HMA) therapy. The first patient in this global trial was enrolled at the MD Anderson Cancer Center in December 2015.
ONTX: 3.60 (+0.05)

Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology
GlobeNewswire - Wed Mar 09, 6:01AM CST
-- Online-First Publication Currently Available --
ONTX: 3.60 (+0.05)

Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market
GlobeNewswire - Thu Feb 04, 4:01PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting approval of the Company's request to transfer its listing to the NASDAQ Capital Market from the NASDAQ Global Select Market. The Company's securities will begin trading on the NASDAQ Capital Market effective at the start of trading on Friday, February 5, 2016. The Company's shares will continue to trade on NASDAQ under the symbol "ONTX."
ONTX: 3.60 (+0.05)

Essential Thrombocythemia Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/n57crm/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Essential Thrombocythemia Overview - Therapeutics Development - Pipeline Products for Essential Thrombocythemia - Overview - Pipeline Products for Essential Thrombocythemia - Comparative Analysis - Essential Thrombocythemia - Therapeutics under Development by Companies - Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes - Essential Thrombocythemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Essential Thrombocythemia - Products under Development by Companies - Essential Thrombocythemia - Products under Investigation by Universities/Institutes - Essential Thrombocythemia - Companies Involved in Therapeutics Development - Aop Orphan Pharmaceuticals AG - Galena Biopharma, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation For more information visit http://www.researchandmarkets.com/research/n57crm/essential
INCY: 90.87 (+0.66), ONTX: 3.60 (+0.05), GALE: 0.45 (+0.01), NVS: 82.97 (-0.29)

Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 7:02AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present a company update at the 18 Annual BIO CEO & Investor Conference in New York, NY. The presentation will take place on Monday, February 8 at 4:00 p.m. ET.
ONTX: 3.60 (+0.05)

Onconova Therapeutics Announces Registered Direct Offering
GlobeNewswire - Wed Jan 06, 7:45AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $1.84 million.
ONTX: 3.60 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 165

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 213

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Investment by BrainsWay to Enhance Mental Health Solutions

Updated Category News Views 247

BrainsWay's Expansion Plans and Strategic Investment This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home. Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, it will set a precedent as the first FDA-cleared medical...

Continue Reading
Mary Street Capital: Enhancing Investment Banking Services

Updated Category News Views 300

Mary Street Capital: A New Era in Investment Banking Mary Street Capital has emerged as an innovative investment banking affiliate of Kaufman Rossin, significantly expanding its advisory capabilities. This new venture focuses on addressing the unique needs of family- and founder-owned businesses, particularly those in the middle market that have often felt overlooked by...

Continue Reading
Fluorine-18 Market Growth Driven by Cancer Diagnosis Demand

Updated Category News Views 169

Fluorine-18 Market Growth Context The global fluorine-18 market is on a notable trajectory of growth, anticipated to reach USD 2.54 billion by 2031 from USD 1.85 billion in 2024. This progression is largely influenced by the increasing incidence of cancer and the expanding utilization of nuclear imaging methodologies. The Role of Fluorine-18 in Medical Diagnostics...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 227

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Chargeback Rates Increase Dramatically Amid Visa Changes

Updated Category News Views 320

Surge in Chargebacks Signals Major Industry Changes CLEVELAND — The payments industry is witnessing a seismic shift, with chargebacks soaring by an astonishing 222% year over year. This significant rise has impacted various sectors, including eCommerce, travel, subscription services, and healthcare. Understanding Visa's VAMP Program As Visa introduces its new Acquirer...

Continue Reading